Human Milk Oligosaccharides Market Projected To Grow At A CAGR of 5.5% During The Forecast Period 2020-2025

Increase in application scope in infant formula and functional beverages, rapid technological advancement in the product line, rising awareness of health and increasing dairy industry is anticipated to drive the Human Milk Oligosaccharides (HMO) Market during the forecast period 2020-2025.

The Human Milk Oligosaccharides (HMO) Market growth rate is attributed to the growing concerns among consumers regarding gut health and the growing consumption of dietary supplements is anticipated to bring new opportunities. Human Milk Oligosaccharides (HMOs) act as prebiotics in the human body and help maintain gut health. They promote bacterial growth, especially bifidobacteria genus, in the gut, which helps improve metabolic activity. The antimicrobial protection and prebiotic functions of the product allow them to be used in various food products, including pharmaceutical and medicinal food and infant formulas. 

Human Milk Oligosaccharides are essential components of breast milk. They promote optimal health and help prevent certain diseases among not just infants but adults as well. They support the digestive, immune, and brain development of an infant. In the case of adults, HMO supplements are found to be helpful for increasing beneficial bacteria in the gut. However, breast milk is not available for all infants, which leads to the synthetic production of HMOs through various production methods. Apart from this, the incorporation of human milk oligosaccharides in functional food and beverages promotes the growth of good bacteria and eliminates harmful bacteria, including salmonella, listeria, and campylobacter. Dairy products dominate the functional food market. There is a high demand for functional food and beverages with prebiotic properties.

Europe is the major region dominating the Human Milk Oligosaccharides Market with revenue of $27.06m in 2019 and is forecast to grow at a CAGR of 5.5% during the forecast period of 2020-2025 to generate revenue of $35.70m in 2025. U.S. in North America region is dominating the Human Milk Oligosaccharides Market generating revenue of $12.47m in 2019 owing to presence of numerous prominent infant formula and baby food manufacturers along with technological advancement.

Also, Lacto-N-neotetraose segment accounted for major share in 2019. This segment generated revenue of $10.22m in 2019 and is forecast to be growing at a CAGR of 5.8% during the forecast period 2020-2025. This segment is projected to generate revenue of $13.68m by 2025. The role of Lacto-N-neotetraose (LNnT) in increasing the growth of beneficial bifidobacteria and decreasing the growth of pathogenic bacteria is attracting the manufacturers of food and beverages and food supplements owing to the growing health consciousness among the customers, which is estimated to enhance the growth of the human milk oligosaccharides (HMO) market. 2'-Fucosyllactose (2'FL) segment is poised to show a significant growth during the forecast period 2020-2025 and is projected to grow at a CAGR of 6.2%. Manufacturers of dietary supplements are shifting towards 2’-fucosyllactose (2’FL) owing to its capability of altering the composition and activity of gut microbiota from formula-fed infants receiving complementary feeding and its contribution in the development of healthy gut, which is estimated to propel the growth of the human milk oligosaccharides (HMO) market.

Human Milk Oligosaccharides (HMO) market is poised to receive an upswing owing to beneficial properties such as infection prevention, memory enhancement, brain growth, prebiotic effects, and improvement of intestinal health, the demand for HMOs in the design of infant formulas is growing. Moreover, the market for Human Milk Oligosaccharides (HMO) is poised to rise at a rapid pace during the forecast period 2020-2025 owing towards the rising health awareness rapidly among people in developing countries. In functional food and beverage products and food supplements, human milk oligosaccharides may help to treat certain diseases and high-risk health conditions, which are expected to raise product demand in turn.

The growing demand for ready-to-drink supplements for working women, particularly pregnant and breastfeeding mothers, to ensure that they obtain adequate nutrition at different stages of their lives to meet their needs acts as a driver for market growth. In addition to their growing demand for replacements, the rising number of breastfeeding women to fulfill the need for calcium and protein specifically for women who are lactose intolerant serves as a catalyst for 

Initiatives to raise awareness of the advantages of proper feeding would also present a major aim for growth in the sector. The National Health and Medical Research Council (NHMRC), for instance, publishes infant feeding recommendations in Australia recommending that infants be breastfed exclusively until about 6 months of age and remain the most essential part of the diet of the baby, with the addition of sufficient solid foods, until about 6 months.

Furthermore, market players are centred on taste comfort, so growing demand for ready-to-drink supplements would in turn provide new avenues for market development. Abbott, for instance, offers Pediasure Plus, a full healthy oral nutrition supplement and tube feed for infants with or at risk of developing malnutrition owing to disease.

Jennewein Biotechnologie announces that the U.S. Food and Drug Administration (FDA) issued a “no question” response letter to Jennewein’s supplement of its GRAS Notice GRN571, thereby acknowledging that the HMO 2’-fucosyllactose, a key ingredient in advanced baby formula, made by an alternative bacterial production strain is also Generally Recognized As Safe (GRAS).

The major companies in the Human Milk Oligosaccharides (HMO) market include Glycom A/S, Inbiose NV, Nestle Nutrition, Jennewein Biotechnologies GmbH, DuPont Nutrition, Medolac Laboratories, ZuChem Inc., Elicityl S.A., BASF SE, Glycosyn LLC. In July 2018, Newtrition, BASF’s human nutrition brand, had launched 2’-fucosyllatose (2’-FL), an human milk oligosaccharide for the infant’s nutrition into market by early 2019..

Although there has been product withdrawals and low demand for the product, companies are conducting research and development for perfecting the medical device. Health professionals are rooting for the comeback of Human Milk Oligosaccharides (HMO) with effective products methods. These are the major factors set to buoy the Human Milk Oligosaccharides (HMO) market during 2020-2025.